The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Disc Medicine Inc shares valued at $139,576 were sold by Bitterman Kevin on Aug 22 ’25. At $61.03 per share, Bitterman Kevin sold 2,287 shares. The insider’s holdings dropped to 590,621 shares worth approximately $36.99 million following the completion of this transaction.
Also, Atlas Venture Opportunity Fund purchased 2,287 shares, netting a total of over 136,648 in proceeds.
Before that, Atlas Venture Fund X, L.P. had added 4,080 shares to its account. In a trade valued at $243,780, the Shareholder bought Disc Medicine Inc shares for $59.75 each.
As published in their initiating research note from Truist on July 21, 2025, Disc Medicine Inc [IRON] has been a Buy and the price target has been revised to $86. Earlier on February 27, 2025, TD Cowen initiated its rating. Their recommendation was “a Buy” for IRON stock.
Analyzing IRON Stock Performance
On last trading session, Disc Medicine Inc [NASDAQ: IRON] rose 2.61% to $62.63. The stock’s lowest price that day was $60.575, but it reached a high of $62.64 in the same session. During the last five days, there has been a surge of approximately 3.88%. Over the course of the year, Disc Medicine Inc shares have jumped approximately 31.35%.
Is Disc Medicine Inc subject to short interest?
Stocks of Disc Medicine Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.16 million shares to 2.1 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 2.26 million shares. A decline of -7.45% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.78 of the overall float, the days-to-cover ratio (short ratio) decline to 6.78.
Which companies own the most shares of Disc Medicine Inc (IRON)?
In terms of Disc Medicine Inc share price expectations, FactSet research, analysts set an average price target of 70.5 in the next 12 months, up nearly 15.52% from the previous closing price of $61.03. Analysts anticipate Disc Medicine Inc stock to reach 112 by 2025, with the lowest price target being 43. In spite of this, 9 analysts ranked Disc Medicine Inc stock as Buy at the end of 2025. On November 05, 2024, Morgan Stanley assigned a price target of “an Overweight” to the stock and upgraded coverage with a $85.
